Heart Diseases Cies Search Engine [selected websites]

Wednesday, May 18, 2011

Physio-Control : New Hospital Solutions for the LIFEPAK 15 Monitor/Defibrillator

Physio-ControlMay 3, 2011 - New Feature Set Includes External AC/DC Power and Temperature Monitoring for Therapeutic Hypothermia PatientsPhysio-Control, Inc., a global leader in emergency medical solutions and wholly‐owned subsidiary of Medtronic, Inc. (NYSE: MDT), announced availability of new solutions for the LIFEPAK® 15 monitor/defibrillator designed to help hospital, as well as pre-hospital, teams provide more effective patient care. The 15, when used together with CODE-STAT™ data review software and the LIFENET® System data network, empowers hospital and pre-hospital care teams with a powerful new suite of tools that utilize patient, performance and device data to improve care, trim operational costs and streamline equipment management.

The new solutions strengthen the 15’s position as the most clinically- and operationally-advanced monitor/defibrillator available for emergency medical teams, and include :

  • External AC/DC power – Ideal for hospital use or in emergency medical services (EMS) vehicles with AC power. The external power adapter charges the batteries while connected to AC or DC power, providing up to 6 hours of battery run time, and features a break-away connector allowing for immediate portability. New on-screen indicators display external power status and battery charging state.
  • Continuous temperature monitoring – Allows clinicians to continuously monitor temperature for therapeutic hypothermia and other critical patients. Patient temperature data can be displayed, saved and transmitted with other monitoring parameters and trended during post-event review with CODE-STAT.
  • Continuous waveform capture and storage – Saves waveform data from all three channels (ECG, SpO2, CO2), allowing for more complete post-event review in CODE-STAT. Clinicians can now correlate capnography waveforms with changes in a patient’s status. Additionally, STJ values are now included on the 12-lead ECG printout to help clinicians identify critical changes.
  • Automated self-reporting capabilities – Important device information such as device readiness, usage data and battery information can be combined with LIFENET® Asset to provide customers with a new level of insight into their device readiness, simplifying management of setup options and allowing customers to perform their own device software updates.

medtronic
“The LIFEPAK 15 monitor was designed as a platform that allows for continuous innovation. These hospital solutions for the 15 add new clinical capabilities, providing clinicians with the broadest selection of monitoring options available,” said Brian Webster, president, Physio-Control, Inc. “With therapeutic hypothermia treatment for cardiac arrest patients already commonplace in hospitals and increasing in EMS use, we expect the new continuous temperature monitoring to be adopted rapidly by customers.”... Physio-Control's Press Release -

Thursday, May 5, 2011

CardioDx : Ability of Corus CAD to Identify Obstructive Coronary Artery Disease and Add Independent Information to Coronary Calcium Scoring by CT...

CardioDxApril 5, 2011 - New Multi-center Trial Results Demonstrate Ability of Corus CAD to Identify Obstructive Coronary Artery Disease and Add Independent Information to Coronary Calcium Scoring by CT Angiography - Results Presented at American College of Cardiology’s Scientific SessionsCardioDx, a pioneer in the field of cardiovascular genomic diagnostics, announced that data presented at the American College of Cardiology’s 60th Annual Scientific Sessions demonstrate the ability of Corus™ CAD, a blood-based gene expression test, to identify obstructive coronary stenosis while adding independent information to coronary calcium scoring in patients undergoing CT angiography. In this study, the negative predictive value of Corus CAD for identifying obstructive coronary artery disease as assessed by CT angiography exceeded 95%.

“The results of this independent cohort provide new support for the high negative predictive value of the Corus CAD test in the identification of obstructive coronary artery disease in stable patients being noninvasively assessed,” said Szilard Voros, M.D., of The Piedmont Heart Institute Physicians group in Atlanta, the investigator who presented the results. “The ability of gene expression testing to provide independent information to a noninvasive imaging modality like coronary calcium scoring can empower more comprehensive decision-making about patient management.”... CardioDx's Press Release -